Exploratory endpoint
tumor
PRIMARY TUMOR, TUMOR
In order to identify reliable biomarkers for responders, bulk RNA-seq and immunohistochemical (IHC) score were conducted on the primary tumor. Additionally, to explore the molecular characteristics of tumor microenvironment (TME), RNA-seq was performed on the primary tumor and lymph-node (LN) samples at pre-treatment (baseline) and post-treatment phases (Fig. 